US FDA warns of kidney failure link to Reclast/Aclasta
This article was originally published in Scrip
Executive Summary
The US FDA on 1 September said the labelling for Novartis’ Reclast (zoledronic acid) has been revised to warn about a rare, but increased serious risk of kidney failure in patients with a history of or risk factors for renal impairment.